Pd17-03 Descriptive Tumor Characteristics of 992 Consecutive Patients Who Underwent Staging With Psma Pet/Ct Before Radical Prostatectomy

You have accessJournal of UrologyProstate Cancer: Staging I (PD17)1 May 2024PD17-03 DESCRIPTIVE TUMOR CHARACTERISTICS OF 992 CONSECUTIVE PATIENTS WHO UNDERWENT STAGING WITH PSMA PET/CT BEFORE RADICAL PROSTATECTOMY Felix Preisser, Florian Nohe, Tobias Maurer, Markus Graefen, and Derya Tilki Felix PreisserFelix Preisser , Florian NoheFlorian Nohe , Tobias MaurerTobias Maurer , Markus GraefenMarkus Graefen , and Derya TilkiDerya Tilki View All Author Informationhttps://doi.org/10.1097/01.JU.0001010044.70939.31.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a novel staging modality for prostate cancer (PCa) patients. To assess the perioperative tumor characteristics of patients staged with PSMA PET/CT prior radical prostatectomy (RP). METHODS: Within a high-volume center database, we identified patients who had a PSMA PET/CT prior to RP between 2016 and 2021. Tumor characteristics of miN0M0 vs. miM1 (+/- miN1) and miN1 patients were assessed. RESULTS: 992 patients who had a PSMA PET/CT prior to RP were identified. Of those, 802 (80.8%) vs. 112 (11.3%) vs. 78 (7.9%) had miN0M0 vs. miN1 vs. miM1 disease. miM1 patients more frequently harbored D'Amico high risk criteria (71.8% and vs. 43.6%, p<0.001), pathologic stage ≥T3b (61.5% vs. 21.8%, p<0.001) and pathologic ISUP grade 4-5 in the prostatectomy specimen (47.4% vs. 13.3%, p<0.001) compared to miN0M0 patients. In patients without neoadjuvant hormone therapy no difference in median PSA prior RP (8.9 ng/ml vs. 9.0 ng/ml, p=0.6) between miM1 and miN0M0 patients were recorded. Similarly, miN1 patients more frequently harbored D'Amico high risk criteria (67.0% vs. 43.6%, p<0.001), pathologic stage ≥T3b (66.1% vs. 21.8%, p<0.001) and pathologic ISUP grade 4-5 in the prostatectomy specimen (44.6% vs. 13.3%, p<0.001) compared to miN0M0 patients. In patients without neoadjuvant hormone therapy miN1 patients had higher median PSA prior RP (12.5 ng/ml vs. 9 ng/ml, p=0.02) compared to miN0M0 patients. CONCLUSIONS: miM1 and miN1 PCa patients in PSMA PET/CT harbor more unfavorable pathologic characteristics compared to miM0miN0 patients during RP. Only small differences in PSA prior to RP were recorded. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e371 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Felix Preisser More articles by this author Florian Nohe More articles by this author Tobias Maurer More articles by this author Markus Graefen More articles by this author Derya Tilki More articles by this author Expand All Advertisement PDF downloadLoading ...